Yttrium-90 combination therapies in hepatocellular carcinoma: current evidence and future directions

Abstract

Yttrium-90 (Y-90) radioembolization, via endovascular delivery of high-dose beta radiation microspheres to tumors, is an invaluable locoregional therapy for hepatocellular carcinoma (HCC). Y-90’s limited off-target radiation exposure enables excellent tumor control with a favorable safety profile. Recent developments suggest that combining targeted radioembolization with systemic treatments, such as molecularly targeted therapies and immune checkpoint inhibitors (ICIs), may offer additive or even synergistic benefits, thereby enhancing both local tumor response and immune activation. This review explores the mechanistic rationale, clinical evidence, and therapeutic strategies involving Y-90 combination therapies in HCC. Data from phase I, II, and III trials suggest improved outcomes with Y-90 plus ICI combination therapy compared with monotherapy. By contrast, trials comparing Y-90 and multi-kinase combination inhibitors with monotherapy have yielded mixed results, highlighting the importance of continued research. Challenges remain in patient selection, optimal sequencing, and toxicity management. To date, no randomized clinical trials have directly compared Y-90 alone with Y-90-based combination therapy, but ongoing trials aim to clarify the role of Y-90 in the evolving systemic treatment landscape. This review highlights the potential of Y-90 combination therapies to enhance the multidisciplinary management of HCC and underscores future research priorities to optimize outcomes.

Keywords

Yttrium-90 / radioembolization / hepatocellular carcinoma / systemic therapy / multi-kinase inhibitors / immune checkpoint inhibitors / combination therapy

References

[1] Bray F,Laversanne M,Sung H.et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA Cancer J Clin. 2024 74 229 63

[2] Singal AG,Llovet JM,Yarchoan M.et al. AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma Hepatology. 2023 78 1922 65 PMC10663390

[3] Galle PR,Forner A,Llovet JM.et al. EASL Clinical Practice Guidelines: management of hepatocellular carcinoma J Hepatol. 2018 69 182 236

[4] Brown AM,Kassab I,Massani M.et al. TACE versus TARE for patients with hepatocellular carcinoma: Overall and individual patient level meta analysis Cancer Medicine. 2022 12 2590 9 PMC9939158

[5] Makary MS,Khandpur U,Cloyd JM,Mumtaz K,Dowell JD. Locoregional therapy approaches for hepatocellular carcinoma: recent advances and management strategies Cancers. 2020 12 1914 PMC7409274

[6] Makary MS,Ramsell S,Miller E,Beal EW,Dowell JD. Hepatocellular carcinoma locoregional therapies: Outcomes and future horizons World J Gastroenterol. 2021 27 7462 79 PMC8613749

[7] Vilgrain V,Pereira H,Assenat E.et al. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial Lancet Oncol. 2017 18 1624 36

[8] Lee YB,Nam JY,Cho EJ.et al. A Phase I/IIa Trial of Yttrium-90 radioembolization in combination with durvalumab for locally advanced unresectable hepatocellular carcinoma Clin Cancer Res. 2023 29 3650 8

[9] Mandlik DS,Mandlik SK,Choudhary HB. Immunotherapy for hepatocellular carcinoma: Current status and future perspectives World J Gastroenterol. 2023 29 1054 75 PMC9950866

[10] Reig M,Forner A,Rimola J.et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update J Hepatol. 2022 76 681 93 PMC8866082

[11] Teo J,Goh BK. Contra-lateral liver lobe hypertrophy after unilobar Y90 radioembolization: an alternative to portal vein embolization? World J Gastroenterol. 2015;21:3170-3 PMC4363745

[12] Molvar C,Lewandowski R. Yttrium-90 radioembolization of hepatocellular carcinoma-performance, technical advances, and future concepts Semin intervent Radiol. 2015 32 388 97

[13] Lewandowski R,Salem R. Yttrium-90 radioembolization of hepatocellular carcinoma and metastatic disease to the liver Semin intervent Radiol. 2006 23 064 72 PMC3036309

[14] Riaz A,Gates VL,Atassi B.et al. Radiation segmentectomy: a novel approach to increase safety and efficacy of radioembolization Int J Radiat Oncol Biol Phys 2011 79 163 71

[15] Busse NC,Al‐ghazi MSAL,Abi‐Jaoudeh N.et al. AAPm medical physics practice guideline 14.a: yttrium-90 microsphere radioembolization J Appl Clin Med Phys. 2023 25 e14157 PMC10860558

[16] Boas FE,Bodei L,Sofocleous CT. Radioembolization of colorectal liver metastases: indications, technique, and outcomes J Nucl Med. 2017 58 Suppl 104S 11S PMC6944173

[17] Wagemans ME,Kunnen B,Stella M.et al. Comparison of 3 different therapeutic particles in radioembolization of locally advanced intrahepatic cholangiocarcinoma J Nucl Med. 2024 65 272 8

[18] Villalobos A,Arndt L,Cheng B.et al. Yttrium-90 radiation segmentectomy of hepatocellular carcinoma: a comparative study of the effectiveness, safety, and dosimetry of glass-based versus resin-based microspheres J Vasc Interv Radiol. 2023 34 1226 34

[19] Gulec SA,Mcgoron AJ. Radiomicrosphere dosimetry: principles and current state of the art Semin Nucl Med. 2022 52 215 28

[20] Garin E,Guiu B,Edeline J,Rolland Y,Palard X. Trans-arterial radioembolization dosimetry in 2022 Cardiovasc Intervent Radiol. 2022 45 1608 21

[21] Feely M,Tondon R,Gubbiotti M.et al. Gastrointestinal tract injury by yttrium-90 appears largely restricted to resin microspheres but can occur years after embolization Am J Surg Pathol. 2022 46 1234 40

[22] Kis B,Gyano M. Radiation pneumonitis after yttrium-90 radioembolization: a systematic review J Vasc Interv Radiol. 2025 36 207 18

[23] Hickey RM,Lewandowski RJ,Salem R. Yttrium-90 radioembolization for hepatocellular carcinoma Semin Nucl Med. 2016 46 105 8

[24] Salem R,Mazzaferro V,Sangro B. Yttrium 90 radioembolization for the treatment of hepatocellular carcinoma: Biological lessons, current challenges, and clinical perspectives: Hepatology Hepatology. 2013 58 2188 97 PMC3732811

[25] Tong AKT,Kao YH,Too CW,Chin KFW,Ng DCE,Chow PKH. Yttrium-90 hepatic radioembolization: clinical review and current techniques in interventional radiology and personalized dosimetry BJR. 2016 89 20150943 PMC5258157

[26] Garin E,Tselikas L,Guiu B.et al. Long-term overall survival after selective internal radiation therapy for locally advanced hepatocellular carcinomas: updated analysis of DOSISPHERE-01 trial J Nucl Med. 2024 65 264 9 PMC10858378

[27] Zhang R,Yao Y,Gao H,Hu X. Mechanisms of angiogenesis in tumour Front. Oncol. 2024 14 1359069 PMC10999665

[28] Wang L,Geng H,Liu Y.et al. Hot and cold tumors: immunological features and the therapeutic strategies MedComm. 2023 4 e343 PMC10458686

[29] Gajewski TF,Schreiber H,Fu Y. Innate and adaptive immune cells in the tumor microenvironment Nat Immunol. 2013 14 1014 22 PMC4118725

[30] Tong J,Tan Y,Ouyang W,Chang H. Targeting immune checkpoints in hepatocellular carcinoma therapy: toward combination strategies with curative potential Exp Hematol Oncol. 2025 14 65 PMC12046748

[31] Ricke J,Klümpen HJ,Amthauer H.et al. Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma J Hepatol. 2019 71 1164 74

[32] Öcal O,Schütte K,Zech CJ.et al. Addition of Y-90 radioembolization increases tumor response and local disease control in hepatocellular carcinoma patients receiving sorafenib Eur J Nucl Med Mol Imaging. 2022 49 4716 26 PMC9606085

[33] Chow PK,Gandhi M,Tan S.et al. ; on behalf of Asia-Pacific Hepatocellular Carcinoma Trials Group. SIRveNIB: selective internal radiation therapy versus sorafenib in asia-pacific patients with hepatocellular carcinoma J Clin Oncol. 2018 36 1913 21

[34] Facciorusso A,Bargellini I,Cela M,Cincione I,Sacco R. Comparison between Y90 radioembolization plus sorafenib and Y90 radioembolization alone in the treatment of hepatocellular carcinoma: a propensity score analysis Cancers. 2020 12 897 PMC7226318

[35] Qin S,Chen M,Cheng A.et al. Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial The Lancet. 2023 402 1835 47

[36] Hack SP,Spahn J,Chen M.et al. IMbrave 050: A phase III trial of atezolizumab plus bevacizumab in high-risk hepatocellular carcinoma after curative resection or ablation Future Oncol. 2020 16 975 89

[37] Yu S,Yu M,Keane B.et al. A pilot study of pembrolizumab in combination with y90 radioembolization in subjects with poor prognosis hepatocellular carcinoma The Oncologist. 2024 29 270 e413 PMC10911903

[38] Tai D,Loke K,Gogna A.et al. Radioembolisation with Y90-resin microspheres followed by nivolumab for advanced hepatocellular carcinoma (CA 209-678): a single arm, single centre, phase 2 trial Lancet Gastroenterol Hepatol. 2021 6 1025 35

[39] Fenton SE,Kircher SM,Mulcahy MF.et al. A phase I study of nivolumab (NIVO) in combination with TheraSphere (Yttrium-90) in patients with advanced hepatocellular cancer J Clin Oncol. 2021 39 e16183

[40] Centers for Disease Control and Prevention. Study of [Atezolizumab and Bevacizumab in Combination With Y^90 Radioembolization in HCC for Liver Transplant]: NCT07059494. CDC. Updated November 4, 2025. https://clinicaltrials.gov/study/NCT07059494. [Accessed on 20 May 2026]

[41] Centers for Disease Control and Prevention. Study of [Efficacy and Safety of Yttrium-90 Microspheres Selective Internal Radiotherapy Combined with Immune Checkpoint Inhibitors and Anti-angiogenesis Drugs Sequential HAIC for Hepatocellular Carcinoma]: NCT06867432. CDC. Updated March 10, 2025. https://clinicaltrials.gov/study/NCT06867432. [Accessed on 20 May 2026]

[42] Centers for Disease Control and Prevention. Study of [Immunotherapy and Radioembolisation for Metastatic Hepatocellular Carcinoma]: NCT05809869. CDC. Updated April 12, 2024. https://clinicaltrials.gov/study/NCT05809869. [Accessed on 20 May 2026]

[43] Salem R,Lewandowski RJ,Mulcahy MF.et al. Radioembolization for hepatocellular carcinoma using yttrium-90 microspheres: a comprehensive report of long-term outcomes Gastroenterology. 2010 138 52 64

[44] Salem R,Lewandowski RJ,Kulik L.et al. Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma Gastroenterology. 2011 140 497 507.e2 PMC3129335

[45] Jones A,Degregorio P,Sung MW,Ramji Z,Ren M,Baron AD. Characterization and management of adverse reactions in patients with unresectable hepatocellular carcinoma treated with lenvatinib JADPRO. 2023 14 598 607 PMC10715287

[46] Kulik L,Vouche M,Koppe S.et al. Prospective randomized pilot study of Y90 +/− sorafenib as bridge to transplantation in hepatocellular carcinoma J Hepatol. 2014 61 309 17

[47] Ramos-casals M,Brahmer JR,Callahan MK.et al. Immune-related adverse events of checkpoint inhibitors Nat Rev Dis Primers. 2020 6 38 PMC9728094

[48] Zhan C,Ruohoniemi D,Shanbhogue KP.et al. Safety of combined yttrium-90 radioembolization and immune checkpoint inhibitor immunotherapy for hepatocellular carcinoma J Vasc Interv Radiol. 2020 31 25 34

[49] Malone CD,Bajaj S,He A.et al. Combining radioembolization and immune checkpoint inhibitors for the treatment of hepatocellular carcinoma: the quest for synergy J Vasc Interv Radiol. 2025 36 414 424.e2

[50] Vogel A,Cervantes A,Chau I.et al. Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Ann Oncol. 2018 29 iv238 55

[51] Riaz A,Ryu RK,Kulik LM.et al. Alpha-fetoprotein response after locoregional therapy for hepatocellular carcinoma: oncologic marker of radiologic response, progression, and survival J Clin Oncol. 2009 27 5734 42

[52] Llovet JM,Di Bisceglie AM,Bruix J.et al. ; for the panel of experts in HCC-Design Clinical Trials. Design and endpoints of clinical trials in hepatocellular carcinoma JNCI: J Nat Cancer I. 2008 100 698 711

[53] Dakal TC,George N,Xu C,Suravajhala P,Kumar A. Predictive and prognostic relevance of tumor-infiltrating immune cells: tailoring personalized treatments against different cancer types Cancers. 2024 16 1626 PMC11082991